A leading supplier of digital pathology solutions, Indica Labs, has declared that its corporate digital pathology platform, HALO AP Dx, for primary diagnosis, has been cleared by the FDA. The 510(k) certification paves the way for the future usage of HALO AP Dx with other FDA-cleared slide scanners and permits its use in conjunction with the Hamamatsu NanoZoomer S360MD Slide scanner for in-vitro diagnostic purposes.
According to company officials, HALO AP is an enterprise digital pathology platform that is used all over the world and has revolutionized the way pathologists and researchers handle, analyze and use digital pathology pictures. Indica Labs developed HALO AP and HALO AP Dx with a full array of diagnostic tools and features for effective and precise image management, evaluation and cooperation in order to meet the complicated demands of contemporary pathology labs.
The company’s dedication to open pathology has resulted in a highly interoperable platform. Users of HALO AP Dx can easily integrate the platform into their current laboratory. It allows them to create a tailored environment for digital pathology and a range of pathologic specializations. Because of its adaptability and ability to be installed in both on-premises and cloud environments, HALO AP Dx gives users complete control over the storage of their data.
A centralized system for primary diagnosis, collaboration, tumor boards and second opinions, HALO AP Dx is a comprehensive pathology platform. Its strong integration engine combines a variety of hardware and software features. Pathology practices benefit from HALO AP Dx by having a collaborative center that encourages creativity, adaptation, and future AI preparedness in addition to a strong diagnostic workspace. Top medical facilities, CROs, clinical labs, governmental agencies and educational institutions rely on HALO AP to deliver the functionality and strength required for contemporary pathology practices.
For more details : https://euroinsightscare.com/
